Parexel announces new C-suite appointments
Leading global clinical research organization (CRO) Parexel appointed Peyton Howell as Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence.
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales and delivery to delight customers, build repeat business and lead the market in the next phase of drug development transformation, said the company in a release.
Ms. Howell has more than 25 years of leadership experience in the healthcare industry, including several leadership positions with AmerisourceBergen, a Fortune 20 company, most recently as President for Health Systems and Specialty Care Solutions, a $50B business unit. Currently she represents Parexel on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and serves on the Board of Directors of Tandem Diabetes Care, a medical device manufacturer.
Dr. McKee joined Parexel in February 2019 as Vice President, Regulatory Consulting Services and prior to joining the company spent 11 years with the FDA during which time she served as Deputy Center Director, Oncology Center of Excellence; Supervisory Associate Director, Office of Hematology and Oncology Products (OHOP) and Deputy Office Director of OHOP.